pHOXBIO Announces Breakthrough Clinical Trial Results Concludi...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
LONDON and NEW YORK, Sept. 22, 2021 /PRNewswire-AsiaNet/-- - pHOXWELL significantly reduced SARS-CoV-2 infection by 63% with tolerability comparable to placebo in high-risk population of healthcare workers- Novel self-administered nasal spray designed to augment existing preventive measures for SARS-CoV...
Authors: LATEST ASIANET NEWS RELEASES